Precision BioSciences, Inc. reported that the first participant in the FUNCTION-DMD clinical trial received an investigational gene-editing treatment, PBGENE-DMD, designed to permanently address the underlying cause of Duchenne muscular dystrophy.
Public source
Publisher name
Public post
September 7 is World Duchenne Awareness Day. Today, we recognize the individuals living with Duchenne muscular dystrophy, as well as the families, caregivers, advocates,…
Company
Precision BioSciences, Inc.
Dedicated to Improving Life.
- Industry
- Biotechnology Research
- Location
- Durham, US
- Company size
- 51–200 employees
About Precision BioSciences, Inc.
Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly complex edits for gene insertion and/or gene repair. Precision BioSciences is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Beam Therapeutics
Beam Therapeutics announced updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency.
Research & Knowledge
Fortrea
Fortrea published an early-stage trial showing that a single-dose experimental gene-editing therapy reduced bad cholesterol and triglycerides in patients for at least 12 months.
Research & Knowledge
Ultragenyx
Ultragenyx published additional analyses from its Phase 3 GlucoGene study of gene therapy to treat glycogen storage disease type Ia in The Journal of Inherited Metabolic Disease.
Research & Knowledge
Prime Medicine, Inc.
Prime Medicine, Inc. published a research paper by the Watts group reporting a practical strategy for purifying long, structurally complex CRISPR guide RNAs using a 5′-terminal dioctyloxytrityl (DOT) protecting group.
Research & Knowledge
ScienTek